Tuesday, July 27, 2021
News

Venus Remedies wins 10-year battle against French firm

   SocialTwist Tell-a-Friend    Print this Page   COMMENT

Chandigarh | Thursday, 2021 10:45:06 PM IST
In a historical breakthrough for the pharmaceutical industry, Venus Remedies Ltd has won a 10-year long legal battle that challenged patent claimed by French firm SCR Pharmatop for producing the intravenous paracetamol solution in India.

In a decision this month, the Indian Patent Office decided in favour of Venus Remedies and upheld its decision for revocation of the Indian patent on the grounds that the process lacked any inventive step that made it superior to other existing solutions.

Venus's opposition was intended to remove any Indian Patent hurdle in manufacturing of intravenous paracetamol solution in India.

As intravenous paracetamol plays a critical role in managing inflammation and fever, hence the revocation of this patent is an encouraging development for the healthcare sector in the country reeling under the current pandemic, said the company in a statement here on Thursday.

Saransh Chaudhary, President, Global Critical Care, Venus Remedies Ltd, said, "We are committed to finding and developing the best solutions for global health challenges the biggest part of which is bridging the gap between people and robust healthcare facilities.

"Our endeavour here was to make sure that critical drugs such as intravenous paracetamol is available in our country to be manufactured generically and accessible at economical prices for the public, particularly during these difficult times."

Venus Remedies filed the post-grant opposition against the SCR Pharmatop's intravenous paracetamol patent in 2011 before Indian Patent Office on several grounds such as lack of novelty and lack of inventive steps, among others.

During the course of the case, Patent Office first revoked the patent in 2018 observing that the claims made by SCR Pharmatop are obvious to an ordinary person skilled in the art. However, the company moved their plea to Delhi High Court and Intellectual Property Appellate Board (IPAB).

IPAB directed the Patent office to again hear the matter and after hearing and written submissions from both the parties, the Indian Patent Office gave its final decision on June 4, maintaining the revocation order of Patent dated December 24, 2018.

--IANS vg/dpb

( 350 Words)

2021-06-17-17:00:04 (IANS)

 
  LATEST COMMENTS (0)
POST YOUR COMMENT
Comments Not Available
 
POST YOUR COMMENT
 
 
TRENDING TOPICS
 
 
CITY NEWS
MORE CITIES
 
 
 
MORE BUSINESS NEWS
ESAF Small Finance Bank files for Rs 998...
Weak global cues subdue equities, Sensex...
India among top 10 countries in pharma, ...
Govt to sell 8% stake in HUDCO via OFS o...
Tata Motors' consolidated net loss narro...
Axis Bank's Q1FY22 YoY net profit rises ...
More...
 
INDIA WORLD ASIA
First-of-its-kind Centre of Excellence t...
Hyderabad: Doctors hold protest after as...
Congress' Shaktisinh Gohil gives suspens...
Pornography case: Bombay HC to hear Raj ...
Parliament not functioning as legitimate...
Congress targets BJP over Yediyurappa st...
More...    
 
 Top Stories
Cong MP Gaurav Gogoi moves adjournm... 
Banking, metal stocks lead rally at... 
Rajnath Singh to leave for Tajikist... 
Tokyo Olympics: Indian shooters fai... 
China's projects on Yarlung Tsangpo... 
Tokyo Olympics: India men's doubles... 
Hitanshu Jinsi, Meghan Jadav talk a... 
3 Beijing districts issue red alert...